title: Effects of kaixin jieyu decoction on behavior and glial fibrillary acidic protein expression in cerebral hippocampus of a rat vascular depression model.
abstract: OBJECTIVE
  To explore the effects and anti-depression mechanisms of Kaixin Jieyu Decoction (, KJD).
  
  
  METHODS
  The rat vascular depression (VD) model was established by ligation of bilateral common carotid arteries (LBCCA) combined with chronic unpredictable mild stress (CUMS). Forty Wistar rats were randomly divided into sham, VD model, VD + high-dose KJD [15.4 g/(kg·d) of crude drug], VD + medium-dose KJD [7.7 g/(kg·d) of crude drug], and VD + fluoxetine [2.4 mg/(kg·d)] groups (n=8 in each group), and the treatments lasted for 21 days. Changes of behavior and hippocampus pathology were observed. The level of glial fibrillary acidic protein (GFAP) protein and mRNA in hippocampus was detected respectively by immunohistochemistry and real-time polymerase chain reaction.
  
  
  RESULTS
  Compared with the sham group, rats in model group showed a variety of behavioral obstacles, including a significant reduction in sucrose consumption percentage, horizontal and vertical activity scores in open-field tests (P<0.05 or P<0.01), pathological damage like neuronal degeneration, necrosis, and a significant decrease of GFAP protein and mRNA in hippocampus (P<0.01); compared with the model group, rats in the high-dose KJD group, medium-dose KJD group and fluoxetine group obtained notable higher behavioral scores, and pathological injury lessened in hippocampus with a increased expression of GFAP protein and mRNA P<0.05 or P<0.01); compared with the medium-dose KJD group and fluoxetine group, GFAP mRNA in high-dose KJD group expressed higer (P<0.05).
  
  
  CONCLUSIONS
  LBCCA combined with CUMS may cause depression-like behavioral changes resulting in the VD model of rats whose depression state can be ameliorated by KJD, and the mechanism of cerebral protection is related possibly with promoting expression of GFAP in hippocampus.
authors.affiliation: Traditional Chinese Medicine Research and Development Center, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
authors.forename: Xian-hui
authors.initials: XH
authors.lastname: Zhang
authors.forename: Shi-jing
authors.initials: SJ
authors.lastname: Huang
authors.forename: Yan-yun
authors.initials: YY
authors.lastname: Wang
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.forename: Ju-hua
authors.initials: JH
authors.lastname: Pan
authors.forename: Jun
authors.initials: J
authors.lastname: Zheng
authors.forename: Duo-jiao
authors.initials: DJ
authors.lastname: Li
authors.forename: Xiao-ming
authors.initials: XM
authors.lastname: Lei
mesh_terms: D000818:Animals; D001522:Behavior, Animal; D003863:Depression / Q000188:drug therapy* / Q000235:genetics; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D004587:Electrophoresis, Agar Gel; D005904:Glial Fibrillary Acidic Protein / Q000235:genetics / Q000378:metabolism*; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D007150:Immunohistochemistry; D008297:Male; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D017208:Rats, Wistar; D044366:Transition Temperature
chemical_list: D004365:Drugs, Chinese Herbal; D005904:Glial Fibrillary Acidic Protein; D012333:RNA, Messenger; C000603459:kaixin jieyu
references.citation: Brain Res. 2007 Apr 20;1142:119-26
references.pmid: 17306230
references.citation: Psychopharmacology (Berl). 1997 Dec;134(4):319-29
references.pmid: 9452163
references.citation: Int J Biochem Cell Biol. 2007;39(4):661-5
references.pmid: 17141551
references.citation: Arch Gen Psychiatry. 2010 Mar;67(3):277-85
references.pmid: 20194828
references.citation: Eur Neuropsychopharmacol. 2009 Nov;19(11):796-805
references.pmid: 19616923
references.citation: Chin J Integr Med. 2014 Apr;20(4):280-5
references.pmid: 24567255
references.citation: N Engl J Med. 2008 Jan 3;358(1):55-68
references.pmid: 18172175
references.citation: Mol Psychiatry. 2010 May;15(5):501-11
references.pmid: 18825147
references.citation: J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):638-40
references.pmid: 17210630
references.citation: J Psychopharmacol. 2009 May;23(3):295-304
references.pmid: 18562439
references.citation: Neuropsychopharmacology. 2004 Nov;29(11):2088-96
references.pmid: 15238995
references.citation: Neuropsychopharmacology. 2006 Aug;31(8):1616-26
references.pmid: 16395301
references.citation: Nat Rev Neurosci. 2006 Feb;7(2):137-51
references.pmid: 16429123
references.citation: Behav Brain Res. 2005 Nov 30;165(1):63-71
references.pmid: 16154211
references.citation: Neurosci Bull. 2010 Aug;26(4):297-303
references.pmid: 20651811
references.citation: Neuroscience. 2005;133(2):453-61
references.pmid: 15885920
references.citation: Brain Res. 2007 May 29;1149:157-64
references.pmid: 17433269
references.citation: J Cereb Blood Flow Metab. 2003 Feb;23(2):137-49
references.pmid: 12571445
references.citation: Lancet. 2006 May 27;367(9524):1747-57
references.pmid: 16731270
references.citation: Neuroscience. 2009 Mar 17;159(2):915-25
references.pmid: 19000745